Calculated Under Revenue Guidance In Effect Before Topic 606 was Alaunos Therapeutics’s largest revenue line in fiscal 2018, bringing in $4.88M of $146.00K (3341%).
| Initial Application Period Cumulative Effect Transition | FY 2018 |
|---|---|
| Calculated Under Revenue Guidance In Effect Before Topic 606 | $4.88M |
| Difference Between Revenue Guidance In Effect Before & After Topic 606 | -$4.73M |
| Total | $146.00K |
Alaunos Therapeutics brought in $146.00K from its two revenue lines in fiscal 2018, the year ended December 31, 2018. Calculated Under Revenue Guidance In Effect Before Topic 606 was the largest at $4.88M (3,341.1%).
The total is net of Difference Between Revenue Guidance In Effect Before & After Topic 606, which took $4.73M off revenue in fiscal 2018.
Alaunos Therapeutics (TCRT) reports its revenue by initial application period cumulative effect transition. In fiscal 2018, Calculated Under Revenue Guidance In Effect Before Topic 606 was its largest revenue line, bringing in $4.88M (3,341.1% of the total).
Calculated Under Revenue Guidance In Effect Before Topic 606 was Alaunos Therapeutics' largest revenue line in fiscal 2018, bringing in $4.88M, or 3,341.1% of the $146.00K total across its two revenue lines.
Every figure comes from Alaunos Therapeutics' annual financial filings, as reported. Each line keeps the name Alaunos Therapeutics gives it, and years follow its fiscal calendar.
Alaunos Therapeutics' revenue by initial application period cumulative effect transition goes back to fiscal 2018, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.